Synthetic Lethality of SHP2 and XIAP Suppresses Proliferation and Metastasis in KRAS ‐mutant Nonsmall Cell Lung Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202411642 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Nai-Jie Fu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, 610041, China. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Biological Resources Program, Chinese Academy of Sciences, Frontier Cross-cutting Projects of Chengdu Institute of Biology, Chinese Academy of Sciences.
Abstract (Originalsprache)
Kirsten rat sarcoma viral oncogene homolog ( KRAS ) mutations are associated with poor prognosis and poor response to standard therapeutic regimens in patients with nonsmall cell lung cancer (NSCLC). Identification of novel synthetic lethal partners in oncogenic KRAS is an alternative therapeutic strategy for KRAS ‐mutant malignancies. After high‐throughput screening against a preclinical/clinical compound library, embelin, a known X‐linked inhibitor of apoptosis protein (XIAP) inhibitor, specifically inhibits the catalytic activity and phosphorylation of Src homology domain 2 containing tyrosine phosphatase 2 (SHP2) in KRAS ‐mutant NSCLC cells. Pharmacological inhibition and genetic knockdown of XIAP and SHP2 induce synthetic lethality in KRAS ‐mutated NSCLC cells and xenograft animal models. Mechanistically, dual inhibition of XIAP and SHP2 by embelin lessens the proliferation and metastasis, activates senescence and endogenous apoptosis, inhibits cancer‐related RAS/mitogen‐activated protein kinase (MAPK), phosphoinositide‐3‐kinase (PI3K)/AKT, Janus kinase/signal transducers and activators of transcription (JAK/STAT), wingless‐related integration site (Wnt), and nuclear factor kappa B (NF‐κB) signaling pathways, and overcomes compensatory feedback in the MAPK signals through the modulation of mitogen‐inducible gene‐6 (MIG‐6) and SPROUTY2 (SPRY2). Collectively, SHP2 and XIAP are potential synthetic lethal partners, and embelin warrants further development as a novel therapeutic option for alleviating KRAS ‐mutant NSCLC by cotargeting SHP2 and XIAP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, 610041, China.
- College of Agriculture, Sichuan Agricultural University, Chengdu, 611130, China.
- University of Chinese Academy of Sciences, Beijing, 100049, China.
ORCID-Profile: Fei Wang
Förderung
- National Natural Science Foundation of China
- Biological Resources Program, Chinese Academy of Sciences
- Frontier Cross-cutting Projects of Chengdu Institute of Biology, Chinese Academy of Sciences
- Sichuan Province Science and Technology Support Program
Zitieren
APA
Fu, N. J., Sheng, Y. W., Fan, Z., Wu, Z., Li, L. Y., Xi, R. Y., Shi, X. K., Zhang, G. L., & Wang, F. (2025). Synthetic Lethality of SHP2 and XIAP Suppresses Proliferation and Metastasis in KRAS ‐mutant Nonsmall Cell Lung Cancer. Advanced Science. https://doi.org/10.1002/advs.202411642
Vancouver
Fu NJ, Sheng YW, Fan Z, Wu Z, Li LY, Xi RY, et al. Synthetic Lethality of SHP2 and XIAP Suppresses Proliferation and Metastasis in KRAS ‐mutant Nonsmall Cell Lung Cancer. Advanced Science. 2025. doi:10.1002/advs.202411642
BibTeX
@article{Fu2025,
author = {Fu, Nai-Jie and Sheng, Yu-Wen and Fan, Zhe and Wu, Zhao and Li, Ling-Yu and Xi, Rui-Ying and Shi, Xiao-Ke and Zhang, Guo-Lin and Wang, Fei},
title = {Synthetic Lethality of SHP2 and XIAP Suppresses Proliferation and Metastasis in KRAS ‐mutant Nonsmall Cell Lung Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202411642}
}
EUVIMED